WuXi Biologics (Cayman) Inc
F:1FW2
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Intrinsic Value
The intrinsic value of 
WuXi Biologics (Cayman) Inc (1FW2) under the Base Case is 4.84 EUR per share.
Compared with the current market price of 5.6 EUR, the stock appears
Overvalued by 14% .
The intrinsic value is calculated using the DCF method.
Do our valuations actually work? See backtest results .
Cheap or expensive for this stock?
This block shows whether today’s valuation is cheap or expensive compared with the stock’s own history, and what happened after similar valuations in the past.
We compare the gap between the stock’s price and our estimated value over time.
- Undervalued can still be historically expensive. The stock may trade below our estimated value, but usually offer an even bigger discount.
- Overvalued can still be historically cheap. The stock may trade above our estimated value, but usually carry an even higher premium.
Market expectations can differ from our model, which may not fully capture everything affecting the price. That is why some stocks regularly trade above our estimated value and others below it.
The scale and chart show how today’s valuation compares with the past. The cards summarize past returns and waiting times until the stock stopped being cheap or expensive. This can happen because the price changed, our estimated value changed, or both.
Only completed periods are included. These are past results, not forecasts. The usual historical range does not necessarily mean fair value.
Fundamental Analysis
What WuXi Biologics (Cayman) Does
WuXi Biologics is a contract development and manufacturing company for biologic drugs, such as antibodies and other protein-based medicines. It helps drug makers move a biologic from early research through process development, testing, and commercial manufacturing, rather than making medicines for its own brand. Its customers are mainly pharmaceutical and biotech companies that need outside expertise, lab capacity, and production scale.
- Headquarters
- China CN
- Employees
- 13 252
- IPO date
- Jun 13, 2017
WuXi Biologics (Cayman) has a narrow economic moat
Moving an established drug-production process away from WuXi Biologics can take substantial time and money, making customers reluctant to switch simply for a lower price. Some customers also owe technology royalties when using another manufacturer, giving WuXi protection beyond the manufacturing work itself.
Read the full moat analysis
Earnings Waterfall
WuXi Biologics (Cayman) Inc
What is the Intrinsic Value of one 1FW2 stock?
The intrinsic value for WuXi Biologics (Cayman) Inc (1FW2) under the Base Case is 4.84 EUR.
Is 1FW2 stock undervalued or overvalued?
Compared with the current market price of 5.6 EUR, the stock appears Overvalued by 14% .
